Merck Acquires Afferent, and Potential Treatments for Chronic Cough, for $500M

Merck Acquires Afferent, and Potential Treatments for Chronic Cough, for $500M

Merck is acquiring Afferent Pharmaceuticals — including its therapeutic candidates targeting the P2X3 receptor, now in clinical testing for neurogenic conditions that include chronic respiratory diseases — under a definitive agreement announced by the two companies. A lead investigational drug developed by Afferent, AF-219, is under evaluation in a Phase 2b dose-escalating study (…

IPF and Health Care Policy: Values of Patients and Society

https://vimeo.com/169925324 Pulmonary fibrosis is a disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. Most of the time, the cause of how it develops is unknown and in these cases, it’s called idiopathic (unknown cause) pulmonary fibrosis. In this video, shared by the Institute…

Cardiovascular Co-Morbidities in IPF Patients May Worsen Prognosis

Patients with idiopathic pulmonary fibrosis (IPF) often exhibit cardiovascular manifestations that affect patients’ morbidity and mortality according to the study”Cardiac manifestations of idiopathic pulmonary fibrosis,” published in Intractable and Rare Diseases Research. The authors reviewed evidence that links cardiovascular diseases to IPF and how the co-morbidities…

What is Idiopathic Pulmonary Fibrosis?

What is idiopathic pulmonary fibrosis (IPF)? IPF is a rare lung disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. This scarring of the lung tissue causes IPF patients to experience severe difficulties in breathing among other serious symptoms. In this animated…

What Do IPF Patients Value and What Needs to Be Considered?

https://vimeo.com/169933079 Pulmonary fibrosis is a disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. Most of the time, the cause of how it develops is unknown and in those cases, it’s called idiopathic (unknown cause) pulmonary fibrosis. In this video, shared by Institute of…